Edition:
United Kingdom

Second Sight Medical Products Inc (EYES.OQ)

EYES.OQ on NASDAQ Stock Exchange Capital Market

1.71USD
16 Feb 2018
Change (% chg)

-- (--)
Prev Close
$1.71
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
124,450
52-wk High
$2.58
52-wk Low
$0.90

Chart for

About

Second Sight Medical Products, Inc. is engaged in developing, manufacturing and marketing prosthetic devices that restore vision to blind individuals. The Company's product, the Argus II System, treats outer retinal degenerations, such as retinitis pigmentosa (RP). The Argus II System provides an artificial form of vision that... (more)

Overall

Beta: --
Market Cap(Mil.): $65.31
Shares Outstanding(Mil.): 56.79
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 32.19 16.60
EPS (TTM): -- -- --
ROI: -- 13.90 10.66
ROE: -- 16.72 14.30

BRIEF-Second Sight Announces Market Entry Into Singapore With First Implant Of Argus II Retinal Prosthesis System

* SECOND SIGHT ANNOUNCES MARKET ENTRY INTO SINGAPORE WITH FIRST IMPLANT OF ARGUS II RETINAL PROSTHESIS SYSTEM Source text for Eikon: Further company coverage:

16 Feb 2018

BRIEF-SECOND SIGHT RECEIVES FDA EXPEDITED ACCESS PATHWAY DESIGNATION FOR ORION SYSTEM

* SECOND SIGHT RECEIVES FDA EXPEDITED ACCESS PATHWAY DESIGNATION FOR THE ORION CORTICAL VISUAL PROSTHESIS SYSTEM

08 Nov 2017

BRIEF-Second Sight Medical Products reports Q3 loss per share $0.12

* Second Sight Medical Products Inc - qtrly adjusted loss per share $0.11 Source text for Eikon: Further company coverage:

02 Nov 2017

BRIEF-Second Sight receives FDA approval to begin first Orion human clinical study

* Second Sight receives full FDA approval to begin first Orion human clinical study

02 Nov 2017

BRIEF-Second Sight Medical Products files for mixed shelf of upto $100 mln‍​

* Second Sight Medical Products Inc files for mixed shelf of upto $100 million - sec filing‍​ Source text : http://bit.ly/2gXz4DE Further company coverage:

31 Oct 2017

BRIEF-Second sight receives German approval to begin study to implant and evaluate Argus II in better-sighted retinitis pigmentosa patients

* Second Sight receives approval from Bundesinstitut Für Arzneimittel Und Medizinprodukte in Germany to begin study to implant and evaluate Argus II in better-sighted retinitis pigmentosa patients Source text for Eikon: Further company coverage:

17 Oct 2017

BRIEF-Second Sight receives conditional FDA approval to begin first Orion human clinical study

* Second sight receives conditional FDA approval to begin first Orion human clinical study

28 Aug 2017

Earnings vs. Estimates